- Home
- SYRE vs MDXG Comparison
SYRE vs MDXG Comparison
Compare SYRE & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- MDXG
- Stock Information
- Founded
- SYRE 2013
- MDXG 2006
- Country
- SYRE United States
- MDXG United States
- Employees
- SYRE 60
- MDXG N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- SYRE Health Care
- MDXG Health Care
- Exchange
- SYRE Nasdaq
- MDXG Nasdaq
- Market Cap
- SYRE 897.9M
- MDXG 1.2B
- IPO Year
- SYRE 2016
- MDXG N/A
- Fundamental
- Price
- SYRE $15.30
- MDXG $7.50
- Analyst Decision
- SYRE Strong Buy
- MDXG Strong Buy
- Analyst Count
- SYRE 8
- MDXG 3
- Target Price
- SYRE $51.50
- MDXG $12.00
- AVG Volume (30 Days)
- SYRE 651.5K
- MDXG 527.3K
- Earning Date
- SYRE 05-08-2025
- MDXG 04-29-2025
- Dividend Yield
- SYRE N/A
- MDXG N/A
- EPS Growth
- SYRE N/A
- MDXG N/A
- EPS
- SYRE N/A
- MDXG 0.28
- Revenue
- SYRE N/A
- MDXG $348,879,000.00
- Revenue This Year
- SYRE N/A
- MDXG $10.09
- Revenue Next Year
- SYRE N/A
- MDXG $11.77
- P/E Ratio
- SYRE N/A
- MDXG $27.14
- Revenue Growth
- SYRE N/A
- MDXG 8.52
- 52 Week Low
- SYRE $15.26
- MDXG $5.47
- 52 Week High
- SYRE $40.84
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- SYRE 32.29
- MDXG 36.84
- Support Level
- SYRE $16.71
- MDXG $7.41
- Resistance Level
- SYRE $18.28
- MDXG $8.12
- Average True Range (ATR)
- SYRE 1.21
- MDXG 0.23
- MACD
- SYRE -0.13
- MDXG -0.03
- Stochastic Oscillator
- SYRE 1.29
- MDXG 12.50
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.